Bicalutamide (BioDeep_00000397768)

Main id: BioDeep_00000001531

 

natural product


代谢物信息卡片


(2R)-N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide

化学式: C18H14F4N2O4S (430.061)
中文名称: 毕卡鲁胺
谱图信息: 最多检出来源 Rattus norvegicus(general) 33.88%

分子结构信息

SMILES: C(C(CS(=O)(=O)C1C=CC(=CC=1)F)(C)O)(=O)NC2C=C(C(=CC=2)C#N)C(F)(F)F
InChI: InChI=1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25)

描述信息

L - Antineoplastic and immunomodulating agents > L02 - Endocrine therapy > L02B - Hormone antagonists and related agents > L02BB - Anti-androgens
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists > D000726 - Androgen Antagonists
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C146993 - Androgen Receptor Inhibitor
C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist > C242 - Anti-Androgen
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials
D000970 - Antineoplastic Agents
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS
CONFIDENCE standard compound; INTERNAL_ID 519; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4405; ORIGINAL_PRECURSOR_SCAN_NO 4401
CONFIDENCE standard compound; INTERNAL_ID 519; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4432; ORIGINAL_PRECURSOR_SCAN_NO 4429
CONFIDENCE standard compound; INTERNAL_ID 519; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4382; ORIGINAL_PRECURSOR_SCAN_NO 4377
CONFIDENCE standard compound; INTERNAL_ID 519; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4426; ORIGINAL_PRECURSOR_SCAN_NO 4422
CONFIDENCE standard compound; INTERNAL_ID 519; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4399; ORIGINAL_PRECURSOR_SCAN_NO 4398
CONFIDENCE standard compound; INTERNAL_ID 519; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4400; ORIGINAL_PRECURSOR_SCAN_NO 4397
CONFIDENCE standard compound; INTERNAL_ID 2349
CONFIDENCE standard compound; INTERNAL_ID 8615
CONFIDENCE standard compound; EAWAG_UCHEM_ID 2809

同义名列表

4 个代谢物同义名

Bicalutamide; Bicalutamide (Casodex); (2R)-N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide; Bicalutamide



数据库引用编号

66 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表
Cytoplasm 14 AKT1, AR, BCL2, CASP3, CDKN1A, EGFR, ERBB2, MSMP, MTOR, PIK3CA, PTEN, STAT3, TNK1, TP53
Peripheral membrane protein 2 MTOR, TNK1
Endosome membrane 2 EGFR, ERBB2
Endoplasmic reticulum membrane 4 BCL2, CYP19A1, EGFR, MTOR
Nucleus 13 ACP3, AKT1, AR, BCL2, CASP3, CDKN1A, EGFR, ERBB2, KLK3, MTOR, PTEN, STAT3, TP53
cytosol 12 ACP3, AKT1, AR, BCL2, CASP3, CDKN1A, ERBB2, MTOR, PIK3CA, PTEN, STAT3, TP53
dendrite 1 MTOR
nuclear body 1 CDKN1A
phagocytic vesicle 1 MTOR
centrosome 1 TP53
nucleoplasm 10 AKT1, AR, CASP3, CDKN1A, ERBB2, MTOR, PTEN, STAT3, TMPRSS2, TP53
RNA polymerase II transcription regulator complex 1 STAT3
Cell membrane 4 AKT1, EGFR, ERBB2, TMPRSS2
Cytoplasmic side 1 MTOR
lamellipodium 2 AKT1, PIK3CA
ruffle membrane 2 EGFR, ERBB2
Early endosome membrane 1 EGFR
Multi-pass membrane protein 1 CYP19A1
Golgi apparatus membrane 1 MTOR
cell cortex 1 AKT1
cell junction 1 EGFR
cell surface 1 EGFR
glutamatergic synapse 3 AKT1, CASP3, EGFR
Golgi membrane 2 EGFR, MTOR
lysosomal membrane 2 ACP3, MTOR
neuromuscular junction 1 ERBB2
neuronal cell body 1 CASP3
postsynapse 1 AKT1
presynaptic membrane 1 ERBB2
Cytoplasm, cytosol 1 ACP3
Lysosome 2 ACP3, MTOR
endosome 1 EGFR
plasma membrane 11 ACP3, AKT1, AR, EGFR, ERBB2, KLK3, PIK3CA, PTEN, STAT3, TMPRSS2, TNK1
Membrane 10 AKT1, AR, BCL2, CYP19A1, EGFR, ERBB2, MTOR, TMPRSS2, TNK1, TP53
apical plasma membrane 3 EGFR, ERBB2, PTEN
basolateral plasma membrane 2 EGFR, ERBB2
extracellular exosome 3 ACP3, KLK3, TMPRSS2
Lysosome membrane 2 ACP3, MTOR
endoplasmic reticulum 3 BCL2, CYP19A1, TP53
extracellular space 6 ACP3, EGFR, GNRH1, IL6, KLK3, MSMP
perinuclear region of cytoplasm 4 CDKN1A, EGFR, ERBB2, PIK3CA
intercalated disc 1 PIK3CA
mitochondrion 2 BCL2, TP53
protein-containing complex 7 AKT1, AR, BCL2, CDKN1A, EGFR, KLK3, TP53
Microsome membrane 2 CYP19A1, MTOR
filopodium 1 ACP3
postsynaptic density 2 CASP3, PTEN
TORC1 complex 1 MTOR
TORC2 complex 1 MTOR
Single-pass type I membrane protein 3 ACP3, EGFR, ERBB2
Secreted 2 IL6, MSMP
extracellular region 6 ERBB2, GNRH1, IL6, KLK3, PTEN, TMPRSS2
cytoplasmic side of plasma membrane 1 PTEN
Mitochondrion outer membrane 2 BCL2, MTOR
Single-pass membrane protein 1 BCL2
mitochondrial outer membrane 2 BCL2, MTOR
Mitochondrion matrix 1 TP53
mitochondrial matrix 1 TP53
transcription regulator complex 2 STAT3, TP53
Cytoplasm, cytoskeleton, microtubule organizing center, centrosome 1 TP53
Nucleus membrane 1 BCL2
Bcl-2 family protein complex 1 BCL2
nuclear membrane 2 BCL2, EGFR
multivesicular body 1 ACP3
dendritic spine 1 PTEN
cytoplasmic vesicle 1 ERBB2
microtubule cytoskeleton 1 AKT1
nucleolus 2 CDKN1A, TP53
Early endosome 1 ERBB2
apical part of cell 1 ACP3
cell-cell junction 1 AKT1
Single-pass type II membrane protein 1 TMPRSS2
vesicle 1 AKT1
Cell projection, ruffle membrane 1 ERBB2
Cytoplasm, perinuclear region 1 ERBB2
Membrane raft 1 EGFR
pore complex 1 BCL2
Cytoplasm, cytoskeleton 1 TP53
focal adhesion 1 EGFR
spindle 1 AKT1
intracellular vesicle 1 EGFR
Cell projection, dendritic spine 1 PTEN
Nucleus, PML body 3 MTOR, PTEN, TP53
PML body 3 MTOR, PTEN, TP53
Mitochondrion intermembrane space 1 AKT1
mitochondrial intermembrane space 1 AKT1
secretory granule 1 KLK3
nuclear speck 1 AR
receptor complex 2 EGFR, ERBB2
Cell projection, neuron projection 1 PTEN
neuron projection 1 PTEN
ciliary basal body 1 AKT1
chromatin 3 AR, STAT3, TP53
cell projection 1 PTEN
[Isoform 2]: Cell membrane 1 ACP3
site of double-strand break 1 TP53
nuclear envelope 1 MTOR
Endomembrane system 1 MTOR
germ cell nucleus 1 TP53
replication fork 1 TP53
myelin sheath 2 BCL2, ERBB2
basal plasma membrane 2 EGFR, ERBB2
synaptic membrane 1 EGFR
endoplasmic reticulum lumen 1 IL6
nuclear matrix 1 TP53
transcription repressor complex 1 TP53
phosphatidylinositol 3-kinase complex 1 PIK3CA
phosphatidylinositol 3-kinase complex, class IA 1 PIK3CA
azurophil granule membrane 1 ACP3
Schmidt-Lanterman incisure 1 PTEN
Golgi cisterna 1 ACP3
semaphorin receptor complex 1 ERBB2
vesicle membrane 1 ACP3
clathrin-coated endocytic vesicle membrane 1 EGFR
[Isoform 1]: Nucleus 1 TP53
[Transmembrane protease serine 2 catalytic chain]: Secreted 1 TMPRSS2
death-inducing signaling complex 1 CASP3
[Isoform 1]: Cell membrane 1 ERBB2
Cytoplasmic vesicle, phagosome 1 MTOR
cyclin-dependent protein kinase holoenzyme complex 1 CDKN1A
multivesicular body, internal vesicle lumen 1 EGFR
Shc-EGFR complex 1 EGFR
[Isoform 1]: Secreted 1 ACP3
ERBB3:ERBB2 complex 1 ERBB2
interleukin-6 receptor complex 1 IL6
myelin sheath adaxonal region 1 PTEN
BAD-BCL-2 complex 1 BCL2
PCNA-p21 complex 1 CDKN1A
[Isoform alpha]: Secreted 1 PTEN
phosphatidylinositol 3-kinase complex, class IB 1 PIK3CA


文献列表

  • Akira Yokomizo, Masaki Shiota, Futoshi Morokuma, Masatoshi Eto, Hideyasu Matsuyama, Hiroaki Matsumoto, Toshiyuki Kamoto, Naoki Terada, Kazuya Kawahara, Hideki Enokida, Shuichi Tatarano, Naohiro Fujimoto, Katsuyoshi Higasijima, Hideki Sakai, Tomoaki Hakariya, Tsukasa Igawa, Shigetaka Suekane, Tomomi Kamba, Yutaka Sugiyama, Junji Kishimoto, Seiji Naito. GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone-sensitive prostate cancer; KYUCOG-1401. International journal of urology : official journal of the Japanese Urological Association. 2023 Dec; ?(?):. doi: 10.1111/iju.15371. [PMID: 38148124]
  • Berlise Yengwa Bakam, Judith Christiane Ngo Pambe, Timothy Grey, Sebastian Maxeiner, Jochen Rutz, Dieudonne Njamen, Roman A Blaheta, Stéphane Zingue. Cucumis sativus (Cucurbitaceae) seed oil prevents benzo(a)pyrene-induced prostate cancer in vitro and in vivo. Environmental toxicology. 2023 Jun; ?(?):. doi: 10.1002/tox.23830. [PMID: 37310102]
  • Lei Tian, Yanfei Peng, Kuo Yang, Jiasong Cao, Xiaoling Du, Zhixian Liang, Jiandang Shi, Ju Zhang. The ERα-NRF2 signalling axis promotes bicalutamide resistance in prostate cancer. Cell communication and signaling : CCS. 2022 11; 20(1):178. doi: 10.1186/s12964-022-00979-0. [PMID: 36376959]
  • Alicia L Garcia-Costa, Teresa I A Gouveia, M Fernando R Pereira, Adrián M T Silva, Luís M Madeira, Arminda Alves, Mónica S F Santos. Intensification strategies for cytostatics degradation by ozone-based processes in aqueous phase. Journal of hazardous materials. 2022 10; 440(?):129743. doi: 10.1016/j.jhazmat.2022.129743. [PMID: 35963086]
  • Mohammadreza Mahdavijalal, Homayon Ahmad Panahi, Ali Niazi, Atefeh Tamaddon. Preparation of responsive nano-adsorbent to near-infrared laser based on tungsten disulfide for bicalutamide extraction in human biological fluids. Journal of pharmaceutical and biomedical analysis. 2022 Jun; 215(?):114759. doi: 10.1016/j.jpba.2022.114759. [PMID: 35430410]
  • Chiung-Chi Peng, Chang-Rong Chen, Chang-Yu Chen, Kuan-Chou Chen, Robert Y Peng. Bicalutamide may enhance kidney injury in diabetes by concomitantly damaging energy production from OXPHOS and glycolysis. Chemico-biological interactions. 2022 Apr; 356(?):109858. doi: 10.1016/j.cbi.2022.109858. [PMID: 35151640]
  • Karin Welén, Ebba Rosendal, Magnus Gisslén, Annasara Lenman, Eva Freyhult, Osvaldo Fonseca-Rodríguez, Daniel Bremell, Johan Stranne, Åse Östholm Balkhed, Katarina Niward, Johanna Repo, David Robinsson, Anna J Henningsson, Johan Styrke, Martin Angelin, Elisabeth Lindquist, Annika Allard, Miriam Becker, Stina Rudolfsson, Robert Buckland, Camilla Thellenberg Carlsson, Anders Bjartell, Anna C Nilsson, Clas Ahlm, Anne-Marie Fors Connolly, Anna K Överby, Andreas Josefsson. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. European urology. 2022 03; 81(3):285-293. doi: 10.1016/j.eururo.2021.12.013. [PMID: 34980495]
  • Mohammadreza Mahdavijalal, Homayon Ahmad Panahi, Ali Niazi, Atefeh Tamaddon. Near-infrared light responsive dendrimers facilitate the extraction of bicalutamide from human plasma and urine. Biotechnology journal. 2021 Dec; 16(12):e2100299. doi: 10.1002/biot.202100299. [PMID: 34519173]
  • Valerie Carpenter, Tareq Saleh, So Min Lee, Graeme Murray, Jason Reed, Andrew Souers, Anthony C Faber, Hisashi Harada, David A Gewirtz. Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapy. Biochemical pharmacology. 2021 11; 193(?):114765. doi: 10.1016/j.bcp.2021.114765. [PMID: 34536356]
  • Amer Jamalpoor, Charlotte Agh van Gelder, Fjodor A Yousef Yengej, Esther A Zaal, Sante P Berlingerio, Koenraad R Veys, Carla Pou Casellas, Koen Voskuil, Khaled Essa, Carola Me Ammerlaan, Laura Rita Rega, Reini En van der Welle, Marc R Lilien, Maarten B Rookmaaker, Hans Clevers, Judith Klumperman, Elena Levtchenko, Celia R Berkers, Marianne C Verhaar, Maarten Altelaar, Rosalinde Masereeuw, Manoe J Janssen. Cysteamine-bicalutamide combination therapy corrects proximal tubule phenotype in cystinosis. EMBO molecular medicine. 2021 07; 13(7):e13067. doi: 10.15252/emmm.202013067. [PMID: 34165243]
  • Mark J Henderson, Kathleen A Trychta, Shyh-Ming Yang, Susanne Bäck, Adam Yasgar, Emily S Wires, Carina Danchik, Xiaokang Yan, Hideaki Yano, Lei Shi, Kuo-Jen Wu, Amy Q Wang, Dingyin Tao, Gergely Zahoránszky-Kőhalmi, Xin Hu, Xin Xu, David Maloney, Alexey V Zakharov, Ganesha Rai, Fumihiko Urano, Mikko Airavaara, Oksana Gavrilova, Ajit Jadhav, Yun Wang, Anton Simeonov, Brandon K Harvey. A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. Cell reports. 2021 04; 35(4):109040. doi: 10.1016/j.celrep.2021.109040. [PMID: 33910017]
  • Henrique J Cardoso, Marília I Figueira, Cátia V Vaz, Tiago M A Carvalho, Luís A Brás, Patrícia A Madureira, Paulo J Oliveira, Vilma A Sardão, Sílvia Socorro. Glutaminolysis is a metabolic route essential for survival and growth of prostate cancer cells and a target of 5α-dihydrotestosterone regulation. Cellular oncology (Dordrecht). 2021 Apr; 44(2):385-403. doi: 10.1007/s13402-020-00575-9. [PMID: 33464483]
  • Hongwen Cao, Dan Wang, Renjie Gao, Lei Chen, Yigeng Feng. Down regulation of U2AF1 promotes ARV7 splicing and prostate cancer progression. Biochemical and biophysical research communications. 2021 02; 541(?):56-62. doi: 10.1016/j.bbrc.2020.12.111. [PMID: 33477033]
  • Yoko Koh, Atsunari Kawashima, Takeshi Ujike, Akira Nagahara, Kazutoshi Fujita, Hiroshi Kiuchi, Ryoichi Imamura, Yasushi Miyagawa, Norio Nonomura, Motohide Uemura. Failure to achieve castrate level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer. Anti-cancer drugs. 2020 11; 31(10):1099-1102. doi: 10.1097/cad.0000000000000986. [PMID: 32804697]
  • Yu Seob Shin, Dong Sup Lee. Re: Impact of androgen deprivation therapy on volume reduction and lower urinary tract symptoms in patients with prostate cancer. Lower urinary tract symptoms. 2020 09; 12(3):293-294. doi: 10.1111/luts.12310. [PMID: 32924313]
  • Heike Lorenz, Andreas Seidel-Morgenstern. Separation Processes to Provide Pure Enantiomers and Plant Ingredients. Annual review of chemical and biomolecular engineering. 2020 06; 11(?):469-502. doi: 10.1146/annurev-chembioeng-100419-103732. [PMID: 32197049]
  • Claudia Kesch, Veronika Schmitt, Samir Bidnur, Marisa Thi, Eliana Beraldi, Igor Moskalev, Virginia Yago, Mary Bowden, Hans Adomat, Ladan Fazil, John K Jackson, Martin E Gleave. A polymeric paste-drug formulation for intratumoral treatment of prostate cancer. Prostate cancer and prostatic diseases. 2020 06; 23(2):324-332. doi: 10.1038/s41391-019-0190-x. [PMID: 31767941]
  • Gorkem Turkkan, Caner Dogan, Burak Tek. Bicalutamide-associated hallucinations in a metastatic prostate cancer patient: A case report. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2020 Jun; 26(4):1029-1031. doi: 10.1177/1078155219886918. [PMID: 31707924]
  • Harutake Sawazaki, Daiji Araki, Yosuke Kitamura, Kota Yagi. Metabolic changes with degarelix vs leuprolide plus bicalutamide in patients with prostate cancer: a randomized clinical study. World journal of urology. 2020 Jun; 38(6):1465-1471. doi: 10.1007/s00345-019-02937-x. [PMID: 31482294]
  • Kuan-Chou Chen, Chang-Rong Chen, Chang-Yu Chen, Kai-Yi Tzou, Chiung-Chi Peng, Robert Y Peng. Bicalutamide Elicits Renal Damage by Causing Mitochondrial Dysfunction via ROS Damage and Upregulation of HIF-1. International journal of molecular sciences. 2020 May; 21(9):. doi: 10.3390/ijms21093400. [PMID: 32403414]
  • Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology. 2019 11; 96(5):629-640. doi: 10.1124/mol.119.115964. [PMID: 31515284]
  • P Suvarov, J-W Lee, A Vande Wouwer, A Seidel-Morgenstern, A Kienle. Online estimation of optimal operating conditions for simulated moving bed chromatographic processes. Journal of chromatography. A. 2019 Sep; 1602(?):266-272. doi: 10.1016/j.chroma.2019.05.042. [PMID: 31164228]
  • Darren J Bryk, Kenneth W Angermeier, Eric A Klein. A Case of Metastatic Prostate Cancer to the Urethra That Resolved After Androgen Deprivation Therapy. Urology. 2019 Jul; 129(?):e4-e5. doi: 10.1016/j.urology.2019.03.022. [PMID: 30935936]
  • Ved Bhushan Arya, Justin H Davies. Idiopathic gonadotropin-independent precocious puberty - is regular surveillance required?. Journal of pediatric endocrinology & metabolism : JPEM. 2019 Apr; 32(4):403-407. doi: 10.1515/jpem-2018-0419. [PMID: 30849047]
  • Chiung Chi Peng, Chang-Yu Chen, Chang-Rong Chen, Chang-Jui Chen, Kun-Hung Shen, Kuan-Chou Chen, Robert Y Peng. Renal Damaging Effect Elicited by Bicalutamide Therapy Uncovered Multiple Action Mechanisms As Evidenced by the Cell Model. Scientific reports. 2019 03; 9(1):3392. doi: 10.1038/s41598-019-39533-3. [PMID: 30833616]
  • M van Nuland, N Venekamp, N de Vries, K A M de Jong, H Rosing, J H Beijnen. Development and validation of an UPLC-MS/MS method for the therapeutic drug monitoring of oral anti-hormonal drugs in oncology. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2019 Feb; 1106-1107(?):26-34. doi: 10.1016/j.jchromb.2019.01.001. [PMID: 30639947]
  • Adam Bohr, Thais Leite Nascimento, Necati Harmankaya, Johan Juhl Weisser, Yingya Wang, Holger Grohganz, Thomas Rades, Korbinian Löbmann. Efflux Inhibitor Bicalutamide Increases Oral Bioavailability of the Poorly Soluble Efflux Substrate Docetaxel in Co-Amorphous Anti-Cancer Combination Therapy. Molecules (Basel, Switzerland). 2019 Jan; 24(2):. doi: 10.3390/molecules24020266. [PMID: 30642009]
  • Changwen Zhang, Penghao Li, Yingwu Wen, Guowei Feng, Yu Liu, Yangyi Zhang, Yong Xu, Zhihong Zhang. The promotion on cell growth of androgen-dependent prostate cancer by antimony via mimicking androgen activity. Toxicology letters. 2018 May; 288(?):136-142. doi: 10.1016/j.toxlet.2018.02.021. [PMID: 29462692]
  • Chang Hee Kim, Kwang Teack Kim, Jin Kyu Oh, Kyung Jin Chung, Tae Beom Kim, Han Jung, Sang Jin Yoon, Khae Hawn Kim. The Association of A Number of Risk Factors With Depression in Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy. Urology journal. 2018 05; 15(3):104-108. doi: 10.22037/uj.v0i0.4138. [PMID: 29388185]
  • Akihiro Yano, Makoto Kagawa, Hideki Takeshita, Yohei Okada, Makoto Morozumi, Satoru Kawakami. Baseline low serum dehydroepiandrosterone sulfate can predict poor responsiveness to hormone therapy in patients with hormone-naïve prostate cancer with skeletal metastases. International journal of urology : official journal of the Japanese Urological Association. 2017 12; 24(12):861-862. doi: 10.1111/iju.13445. [PMID: 28895205]
  • Bertrand Tombal, Erik B Cornel, Raj Persad, Anny Stari, Francisco Gómez Veiga, Claude Schulman. Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study. The Journal of urology. 2017 11; 198(5):1054-1060. doi: 10.1016/j.juro.2017.05.072. [PMID: 28552710]
  • Yang Zhang, Bo-Han Lei, Qing Zou, Qing-Yi Zhu, Zi-Jie Lu, Yue Wang. [Clinical efficacy of integrated traditional Chinese and Western medicine for castration-resistant prostate cancer]. Zhonghua nan ke xue = National journal of andrology. 2017 Oct; 23(10):922-927. doi: NULL. [PMID: 29727544]
  • Congbin Yang, Peiwen Di, JinPing Fu, Hui Xiong, Qiufang Jing, Guobin Ren, Yun Tang, Wenyun Zheng, Guixia Liu, Fuzheng Ren. Improving the physicochemical properties of bicalutamide by complex formation with bovine serum albumin. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2017 Aug; 106(?):381-392. doi: 10.1016/j.ejps.2017.05.059. [PMID: 28571783]
  • Dante Rojas, Gaud Dervilly-Pinel, Nora Cesbron, Mylène Penot, Alexandre Sydor, Stéphanie Prévost, Bruno Le Bizec. Selective androgen receptor modulators: comparative excretion study of bicalutamide in bovine urine and faeces. Drug testing and analysis. 2017 Jul; 9(7):1017-1025. doi: 10.1002/dta.2113. [PMID: 27726308]
  • Kyu-Pyo Kim, Robert A Parise, Julianne L Holleran, Lionel D Lewis, Leonard Appleman, Nielka van Erp, Michael J Morris, Jan H Beumer. Simultaneous quantitation of abiraterone, enzalutamide, N-desmethyl enzalutamide, and bicalutamide in human plasma by LC-MS/MS. Journal of pharmaceutical and biomedical analysis. 2017 May; 138(?):197-205. doi: 10.1016/j.jpba.2017.02.018. [PMID: 28219796]
  • J Morote, L Regis, A Celma, J Planas. Measurement of serum testosterone during androgenic suppression in patients with prostate cancer: A systematic review. Actas urologicas espanolas. 2016 Oct; 40(8):477-84. doi: 10.1016/j.acuro.2016.01.006. [PMID: 26899928]
  • Huiyan Wang, Lixia Zhang, Ying Fu, Fang Fang, Yong Jiang, Yuan Dong, Wenhe Zhu. CSL regulates AKT to mediate androgen independence in prostate cancer progression. The Prostate. 2016 Feb; 76(2):140-50. doi: 10.1002/pros.23104. [PMID: 26437743]
  • Nada Lallous, Stanislav V Volik, Shannon Awrey, Eric Leblanc, Ronnie Tse, Josef Murillo, Kriti Singh, Arun A Azad, Alexander W Wyatt, Stephane LeBihan, Kim N Chi, Martin E Gleave, Paul S Rennie, Colin C Collins, Artem Cherkasov. Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients. Genome biology. 2016 Jan; 17(?):10. doi: 10.1186/s13059-015-0864-1. [PMID: 26813233]
  • Natalia Mast, Joseph B Lin, Irina A Pikuleva. Marketed Drugs Can Inhibit Cytochrome P450 27A1, a Potential New Target for Breast Cancer Adjuvant Therapy. Molecular pharmacology. 2015 Sep; 88(3):428-36. doi: 10.1124/mol.115.099598. [PMID: 26082378]
  • Masahiro Nozawa, Isao Hara, Hideyasu Matsuyama, Masayuki Iki, Kazuhiro Nagao, Tsukasa Nishioka, Takahiro Komura, Atsunobu Esa, Shigeya Uejima, Masaaki Imanishi, Yasunari Uekado, Takatoshi Ogawa, Hiroshi Kajikawa, Hirotsugu Uemura. Significance of baseline bone markers on disease progression and survival in hormone-sensitive prostate cancer with bone metastasis. World journal of urology. 2015 Sep; 33(9):1263-8. doi: 10.1007/s00345-014-1431-1. [PMID: 25354720]
  • Sho Uehara, Takeshi Yuasa, Yasuhisa Fujii, Akihiro Yano, Shinya Yamamoto, Hitoshi Masuda, Iwao Fukui, Junji Yonese. Prior administration of a non-steroidal anti-androgen failed to prevent the flare-up caused by a luteinizing hormone-releasing hormone agonist in a patient with metastatic prostate cancer. BMC research notes. 2015 Aug; 8(?):335. doi: 10.1186/s13104-015-1297-3. [PMID: 26242866]
  • Jing Li, SongTao Xiang, QiouHong Zhang, JingJing Wu, Qing Tang, JianFu Zhou, LiJun Yang, ZhiQiang Chen, Swei Sunny Hann. Combination of curcumin and bicalutamide enhanced the growth inhibition of androgen-independent prostate cancer cells through SAPK/JNK and MEK/ERK1/2-mediated targeting NF-κB/p65 and MUC1-C. Journal of experimental & clinical cancer research : CR. 2015 May; 34(?):46. doi: 10.1186/s13046-015-0168-z. [PMID: 25971429]
  • Evan Y Yu, Hongli Li, Celestia S Higano, Neeraj Agarwal, Sumanta K Pal, Ajjai Alva, Elisabeth I Heath, Elaine T Lam, Shilpa Gupta, Michael B Lilly, Yoshio Inoue, Kim N Chi, Nicholas J Vogelzang, David I Quinn, Heather H Cheng, Stephen R Plymate, Maha Hussain, Catherine M Tangen, Ian M Thompson. SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 May; 33(14):1601-8. doi: 10.1200/jco.2014.59.4127. [PMID: 25847934]
  • Fu-Chao Liu, See-Tong Pang, Yung-Fong Tsai, Irshad H Chaudry, Huang-Ping Yu. Hepatoprotective effect of casodex after trauma hemorrhage in a rodent model. Shock (Augusta, Ga.). 2015 May; 43(5):470-4. doi: 10.1097/shk.0000000000000339. [PMID: 25692256]
  • Nobuyuki Ishikura, Hiromitsu Kawata, Ayako Nishimoto, Ryo Nakamura, Toshiaki Tsunenari, Miho Watanabe, Kazutaka Tachibana, Takuya Shiraishi, Hitoshi Yoshino, Akie Honma, Takashi Emura, Masateru Ohta, Toshito Nakagawa, Takao Houjo, Eva Corey, Robert L Vessella, Yuko Aoki, Haruhiko Sato. CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells. International journal of oncology. 2015 Apr; 46(4):1560-72. doi: 10.3892/ijo.2015.2860. [PMID: 25634071]
  • Christopher Green, Jayne Brian, Rakesh Kanda, Martin Scholze, Richard Williams, Susan Jobling. Environmental concentrations of anti-androgenic pharmaceuticals do not impact sexual disruption in fish alone or in combination with steroid oestrogens. Aquatic toxicology (Amsterdam, Netherlands). 2015 Mar; 160(?):117-27. doi: 10.1016/j.aquatox.2014.12.022. [PMID: 25630045]
  • Su-bo Qian, Hai-bo Shen, Qi-feng Cao, Lin Zhang, Yi-fan Chen, Jun Qi. Bicalutamide 150 mg as secondary hormonal therapy for castration-resistant prostate cancer. International urology and nephrology. 2015 Mar; 47(3):479-84. doi: 10.1007/s11255-015-0919-y. [PMID: 25665794]
  • Ritu Kudarha, Namdev L Dhas, Abhijeet Pandey, Veena S Belgamwar, Pradum P Ige. Box-Behnken study design for optimization of bicalutamide-loaded nanostructured lipid carrier: stability assessment. Pharmaceutical development and technology. 2015; 20(5):608-18. doi: 10.3109/10837450.2014.908305. [PMID: 24785784]
  • Kyoung-Ah Kim, Yu-Jung Cha, Hae-Mi Lee, Hyun-Jin Joo, Ji-Young Park. Effects of the ABCG2 and ABCB1 drug transporter polymorphisms on the pharmacokinetics of bicalutamide in humans. Clinica chimica acta; international journal of clinical chemistry. 2015 Jan; 438(?):7-11. doi: 10.1016/j.cca.2014.08.006. [PMID: 25124867]
  • Cecilia Fortugno, Toon van der Gronde, Greta Varchi, Andrea Guerrini, Carlo Bertucci. Species-dependent binding of new synthesized bicalutamide analogues to albumin by optical biosensor analysis. Journal of pharmaceutical and biomedical analysis. 2015; 111(?):324-32. doi: 10.1016/j.jpba.2015.02.010. [PMID: 25771488]
  • L Klotz, D Drachenberg, R Singal, A Aprikian, Y Fradet, M Kebabdjian, M Zarenda, J Chin. An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study. Prostate cancer and prostatic diseases. 2014 Dec; 17(4):320-4. doi: 10.1038/pcan.2014.24. [PMID: 25179591]
  • Smita Subramaniam, Elie Choufani, Andrey Manov. Lack of energy, petechiae, elevated PSA level--Dx?. The Journal of family practice. 2014 Oct; 63(10):565-7. doi: NULL. [PMID: 25343154]
  • Arun A Azad, Emma K Beardsley, Sebastian J Hotte, Susan L Ellard, Lawrence Klotz, Joseph Chin, Christian Kollmannsberger, Som D Mukherjee, Kim N Chi. A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer. Investigational new drugs. 2014 Aug; 32(4):746-52. doi: 10.1007/s10637-014-0091-8. [PMID: 24671507]
  • Jiping Yang, Zulin Wang, Li Song, Feng Tian, Zhongwei Yu, Feng Li, Laikun Tang. Clinical research of Tashinone IIA combined with endocrine therapy in treating advanced-stage prostate cancer. Cell biochemistry and biophysics. 2014 Jul; 69(3):503-7. doi: 10.1007/s12013-014-9824-8. [PMID: 24526351]
  • Pekka K Poutiainen, Tuulia Huhtala, Tiina Jääskeläinen, Aleksanteri Petsalo, Jenni Küblbeck, Sanna Kaikkonen, Jorma J Palvimo, Hannu Raunio, Ale Närvänen, Mikael Peräkylä, Risto O Juvonen, Paavo Honkakoski, Reino Laatikainen, Juha T Pulkkinen. Preclinical pharmacology of FL442, a novel nonsteroidal androgen receptor modulator. Molecular and cellular endocrinology. 2014 Apr; 387(1-2):8-18. doi: 10.1016/j.mce.2014.02.008. [PMID: 24565895]
  • Luis Daverede, Christy Ralph, Satinder P Jagdev, Ioannis Trigonis, Sebastian Trainor, Patricia Harnden, Michael Weston, Alan Paul, Naveen S Vasudev. Metastatic castrate-resistant prostate cancer with a late, complete and durable response to docetaxel chemotherapy: a case report. Journal of medical case reports. 2014 Apr; 8(?):122. doi: 10.1186/1752-1947-8-122. [PMID: 24717107]
  • Kazuhiro Matsumoto, Masayuki Hagiwara, Nozomi Hayakawa, Nobuyuki Tanaka, Yujiro Ito, Takahiro Maeda, Akiharu Ninomiya, Hirohiko Nagata, So Nakamura. Third-line hormonal therapy to treat prostate cancer relapse after initial and second-line hormonal therapy: report of 52 cases and literature review. Asian Pacific journal of cancer prevention : APJCP. 2014; 15(8):3645-9. doi: 10.7314/apjcp.2014.15.8.3645. [PMID: 24870772]
  • Bao-Xing Huang, Heng-Chuan Su, Wan-Li Cao, Fu-Kang Sun. [Hormonal therapy for prostate cancer: methods and prognosis]. Zhonghua nan ke xue = National journal of andrology. 2013 Sep; 19(9):815-9. doi: NULL. [PMID: 24386861]
  • Oskar Ragnarsson, Gudmundur Johannsson, Kjell Geterud, Par Lodding, Per Dahlqvist. Inadequate testosterone suppression after medical and subsequent surgical castration in a patient with prostate cancer. BMJ case reports. 2013 Aug; 2013(?):. doi: 10.1136/bcr-2013-010395. [PMID: 23943809]
  • Laurent Grosse, Anne-Sophie Campeau, Sarah Caron, Frédéric-Alexandre Morin, Kim Meunier, Jocelyn Trottier, Patrick Caron, Mélanie Verreault, Olivier Barbier. Enantiomer selective glucuronidation of the non-steroidal pure anti-androgen bicalutamide by human liver and kidney: role of the human UDP-glucuronosyltransferase (UGT)1A9 enzyme. Basic & clinical pharmacology & toxicology. 2013 Aug; 113(2):92-102. doi: 10.1111/bcpt.12071. [PMID: 23527766]
  • Benoît Boutin, Nicolas Tajeddine, Patrick Vandersmissen, Nadège Zanou, Monique Van Schoor, Ludivine Mondin, Pierre J Courtoy, Bertrand Tombal, Philippe Gailly. Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone-resistant prostate cancer cells and confer resistance to apoptosis. The Prostate. 2013 Jul; 73(10):1090-102. doi: 10.1002/pros.22658. [PMID: 23532738]
  • C Erem. Update on idiopathic hirsutism: diagnosis and treatment. Acta clinica Belgica. 2013 Jul; 68(4):268-74. doi: 10.2143/acb.3267. [PMID: 24455796]
  • Christina Teng, Bonnie Goodwin, Keith Shockley, Menghang Xia, Ruili Huang, John Norris, B Alex Merrick, Anton M Jetten, Christopher P Austin, Raymond R Tice. Bisphenol A affects androgen receptor function via multiple mechanisms. Chemico-biological interactions. 2013 May; 203(3):556-64. doi: 10.1016/j.cbi.2013.03.013. [PMID: 23562765]
  • James P Dean, Cynthia C Sprenger, Junxiang Wan, Kathleen Haugk, William J Ellis, Daniel W Lin, John M Corman, Bruce L Dalkin, Elahe Mostaghel, Peter S Nelson, Pinchas Cohen, Bruce Montgomery, Stephen R Plymate. Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation. The Journal of clinical endocrinology and metabolism. 2013 May; 98(5):E820-8. doi: 10.1210/jc.2012-3856. [PMID: 23533230]
  • Eva de Rijke, Martien L Essers, Jeroen C W Rijk, Mario Thevis, Toine F H Bovee, Leendert A van Ginkel, Saskia S Sterk. Selective androgen receptor modulators: in vitro and in vivo metabolism and analysis. Food additives & contaminants. Part A, Chemistry, analysis, control, exposure & risk assessment. 2013; 30(9):1517-26. doi: 10.1080/19440049.2013.810346. [PMID: 23883284]
  • Eleonora Regueira, Alina Grisel Sassone, María Florencia Scaia, María Clara Volonteri, Nora Raquel Ceballos. Seasonal changes and regulation of the glucocorticoid receptor in the testis of the toad Rhinella arenarum. Journal of experimental zoology. Part A, Ecological genetics and physiology. 2013 Jan; 319(1):39-52. doi: 10.1002/jez.1772. [PMID: 23203422]
  • C Salvador, J Planas, F Agreda, J Placer, E Trilla, M A Lopez, J Morote. Analysis of the lipid profile and atherogenic risk during androgen deprivation therapy in prostate cancer patients. Urologia internationalis. 2013; 90(1):41-4. doi: 10.1159/000342814. [PMID: 23235105]
  • Luciano De Petrocellis, Alessia Ligresti, Aniello Schiano Moriello, Mariagrazia Iappelli, Roberta Verde, Colin G Stott, Luigia Cristino, Pierangelo Orlando, Vincenzo Di Marzo. Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms. British journal of pharmacology. 2013 Jan; 168(1):79-102. doi: 10.1111/j.1476-5381.2012.02027.x. [PMID: 22594963]
  • Karol Axcrona, Sirpa Aaltomaa, Carlos Martins da Silva, Haluk Ozen, Jan-Erik Damber, László B Tankó, Enrico Colli, Peter Klarskov. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide. BJU international. 2012 Dec; 110(11):1721-8. doi: 10.1111/j.1464-410x.2012.11107.x. [PMID: 22500884]
  • Kuldeep Sharma, Gopal V Pawar, Sanjeev Giri, Sriram Rajagopal, Ramesh Mullangi. Development and validation of a highly sensitive LC-MS/MS-ESI method for the determination of bicalutamide in mouse plasma: application to a pharmacokinetic study. Biomedical chromatography : BMC. 2012 Dec; 26(12):1589-95. doi: 10.1002/bmc.2736. [PMID: 22495777]
  • María Eugenia Matzkin, Eliana Herminia Pellizzari, Soledad Paola Rossi, Ricardo Saúl Calandra, Selva Beatriz Cigorraga, Mónica Beatriz Frungieri. Exploring the cyclooxygenase 2 (COX2)/15d-Δ(12,14)PGJ(2) system in hamster Sertoli cells: regulation by FSH/testosterone and relevance to glucose uptake. General and comparative endocrinology. 2012 Nov; 179(2):254-64. doi: 10.1016/j.ygcen.2012.08.020. [PMID: 22974512]
  • Ramesh R Kaini, Laurel O Sillerud, Siqin Zhaorigetu, Chien-An A Hu. Autophagy regulates lipolysis and cell survival through lipid droplet degradation in androgen-sensitive prostate cancer cells. The Prostate. 2012 Sep; 72(13):1412-22. doi: 10.1002/pros.22489. [PMID: 22294520]
  • Vincenzo Serretta, Vincenzo Altieri, Giuseppe Morgia, Federico Nicolosi, Gaetano De Grande, Rosaria Mazza, Darwin Melloni, Rosalinda Allegro, Francesco Ferraù, Vittorio Gebbia. A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia. Clinical genitourinary cancer. 2012 Sep; 10(3):174-9. doi: 10.1016/j.clgc.2012.03.002. [PMID: 22502790]
  • Rachel M Squillace, David Miller, Scott D Wardwell, Frank Wang, Tim Clackson, Victor M Rivera. Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models. International journal of oncology. 2012 Aug; 41(2):425-32. doi: 10.3892/ijo.2012.1487. [PMID: 22614157]
  • Jung-Soo Bae, Hyoung-Sook Park, Jong-Wan Park, Shan-Hua Li, Yang-Sook Chun. Red ginseng and 20(S)-Rg3 control testosterone-induced prostate hyperplasia by deregulating androgen receptor signaling. Journal of natural medicines. 2012 Jul; 66(3):476-85. doi: 10.1007/s11418-011-0609-8. [PMID: 22101440]
  • Christian Thomas, Latif A Wafa, Francois Lamoureux, Helen Cheng, Ladan Fazli, Martin E Gleave, Paul S Rennie. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors. The Prostate. 2012 Jun; 72(8):875-85. doi: 10.1002/pros.21490. [PMID: 22072572]
  • Juliet Richards, Ai Chiin Lim, Colin W Hay, Angela E Taylor, Anna Wingate, Karolina Nowakowska, Carmel Pezaro, Suzanne Carreira, Jane Goodall, Wiebke Arlt, Iain J McEwan, Johann S de Bono, Gerhardt Attard. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer research. 2012 May; 72(9):2176-82. doi: 10.1158/0008-5472.can-11-3980. [PMID: 22411952]
  • C Salvador, J Planas, C Raventós, J Ropero, J Placer, M A López, J Morote. [Impact of androgen deprivation on the lipid profile and atherogenic risk in prostate cancer patients]. Actas urologicas espanolas. 2012 Apr; 36(4):205-9. doi: 10.1016/j.acuro.2011.09.006. [PMID: 22178349]
  • Nicola J Clegg, John Wongvipat, James D Joseph, Chris Tran, Samedy Ouk, Anna Dilhas, Yu Chen, Kate Grillot, Eric D Bischoff, Ling Cai, Anna Aparicio, Steven Dorow, Vivek Arora, Gang Shao, Jing Qian, Hong Zhao, Guangbin Yang, Chunyan Cao, John Sensintaffar, Teresa Wasielewska, Mark R Herbert, Celine Bonnefous, Beatrice Darimont, Howard I Scher, Peter Smith-Jones, Mark Klang, Nicholas D Smith, Elisa De Stanchina, Nian Wu, Ouathek Ouerfelli, Peter J Rix, Richard A Heyman, Michael E Jung, Charles L Sawyers, Jeffrey H Hager. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer research. 2012 Mar; 72(6):1494-503. doi: 10.1158/0008-5472.can-11-3948. [PMID: 22266222]
  • Jun Yan, Bingxian Xie, Jillian L Capodice, Aaron E Katz. Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth. The Prostate. 2012 Feb; 72(3):244-52. doi: 10.1002/pros.21426. [PMID: 21656835]
  • H-M Lu, M Ye. The relative bioavailability study and fasting and fed states pharmacokinetics of bicalutamide 50-mg tablets in healthy Chinese volunteers. Arzneimittel-Forschung. 2012 Jan; 62(1):18-21. doi: 10.1055/s-0031-1295429. [PMID: 22331758]
  • Fumio Ito, Nobuyuki Goya, Hayakazu Nakazawa, Toshiaki Suzuki, Keiko Suzuki, Kazuo Kubo, Takeshi Kihara. A study of plasma bicalutamide concentrations in hemodialysis patients. Urologia internationalis. 2012; 89(2):162-5. doi: 10.1159/000339919. [PMID: 22868217]
  • Shinichi Yamashita, Kuo-Pao Lai, Kun-Lung Chuang, Defeng Xu, Hiroshi Miyamoto, Tatsuo Tochigi, See-Tong Pang, Lei Li, Yoichi Arai, Hsing-Jien Kung, Shuyuan Yeh, Chawnshang Chang. ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors. Neoplasia (New York, N.Y.). 2012 Jan; 14(1):74-83. doi: 10.1593/neo.111436. [PMID: 22355276]
  • Chiara Fuccio, Riccardo Schiavina, Paolo Castellucci, Domenico Rubello, Giuseppe Martorana, Monica Celli, Claudio Malizia, Marta Barios Profitos, Maria Cristina Marzola, Vincenzina Pettinato, Stefano Fanti. Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study. European journal of nuclear medicine and molecular imaging. 2011 Nov; 38(11):1985-9. doi: 10.1007/s00259-011-1867-0. [PMID: 21732105]
  • Hiromitsu Kawata, Shinichi Arai, Toshito Nakagawa, Nobuyuki Ishikura, Ayako Nishimoto, Hitoshi Yoshino, Takuya Shiraishi, Kazutaka Tachibana, Ryo Nakamura, Haruhiko Sato. Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291. The Prostate. 2011 Sep; 71(12):1344-56. doi: 10.1002/pros.21351. [PMID: 21308717]
  • Norio Nonomura, Hitoshi Takayama, Masashi Nakayama, Yasutomo Nakai, Atsunari Kawashima, Masatoshi Mukai, Akira Nagahara, Katsuyuki Aozasa, Akira Tsujimura. Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer. BJU international. 2011 Jun; 107(12):1918-22. doi: 10.1111/j.1464-410x.2010.09804.x. [PMID: 21044246]
  • Arne Solberg, Olav A Haugen, Trond Viset, Anders Bergh, Ilker Tasdemir, Göran Ahlgren, Anders Widmark, Anders Angelsen. Residual prostate cancer in patients treated with endocrine therapy with or without radical radiotherapy: a side study of the SPCG-7 randomized trial. International journal of radiation oncology, biology, physics. 2011 May; 80(1):55-61. doi: 10.1016/j.ijrobp.2010.01.072. [PMID: 20598453]
  • Hanna Paatela, Veera Vihma, Matti Jauhiainen, Eero Mervaala, Matti J Tikkanen. Dehydroepiandrosterone fatty acyl esters in high density lipoprotein: interaction with human vascular endothelial cells and vascular responses ex vivo. Steroids. 2011 Mar; 76(4):376-80. doi: 10.1016/j.steroids.2010.12.007. [PMID: 21168430]
  • Seunghwan Lee, Seo Hyun Yoon, Joo-Youn Cho, Sang-Goo Shin, In-Jin Jang, Kyung-Sang Yu. Relative bioavailability and tolerability of two formulations of bicalutamide 50-mg tablets: a randomized-sequence, open-label, two-period crossover study in healthy Korean male subjects. Clinical therapeutics. 2010 Dec; 32(14):2496-501. doi: 10.1016/j.clinthera.2011.01.017. [PMID: 21353117]
  • Michele Lodde, Louis Lacombe, Yves Fradet. Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer. Urology. 2010 Nov; 76(5):1189-93. doi: 10.1016/j.urology.2009.12.057. [PMID: 20303155]
  • Shuang Liu, Yanfeng Qi, Yubin Ge, Tamika Duplessis, Brian G Rowan, Clement Ip, Helen Cheng, Paul S Rennie, Izumi Horikawa, Arthur J Lustig, Qun Yu, Haitao Zhang, Yan Dong. Telomerase as an important target of androgen signaling blockade for prostate cancer treatment. Molecular cancer therapeutics. 2010 Jul; 9(7):2016-25. doi: 10.1158/1535-7163.mct-09-0924. [PMID: 20571066]
  • Takeshi Yuasa, Shinya Maita, Norihiko Tsuchiya, Zhiyong Ma, Shintaro Narita, Yohei Horikawa, Shinya Yamamoto, Junji Yonese, Iwao Fukui, Shunji Takahashi, Kiyohiko Hatake, Tomonori Habuchi. Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients. Urology. 2010 May; 75(5):1131-7. doi: 10.1016/j.urology.2009.10.075. [PMID: 20163839]
  • Fernand Labrie. Hormonal therapy of prostate cancer. Progress in brain research. 2010; 182(?):321-41. doi: 10.1016/s0079-6123(10)82014-x. [PMID: 20541672]
  • SeungHwan Lee, Yong-Ju Chung, Bo-Hyung Kim, Jun-Hwa Shim, Seo-Hyun Yoon, Sang-Goo Shin, In-Jin Jang, Kyung-Sang Yu. Comparative pharmacokinetic evaluation of two formulations of bicalutamide 50-mg tablets: an open-label, randomized-sequence, single-dose, two-period crossover study in healthy Korean male volunteers. Clinical therapeutics. 2009 Dec; 31(12):3000-8. doi: 10.1016/j.clinthera.2009.12.004. [PMID: 20110037]
  • Audrey Dayon, Leyre Brizuela, Claire Martin, Catherine Mazerolles, Nelly Pirot, Nicolas Doumerc, Leonor Nogueira, Muriel Golzio, Justin Teissié, Guy Serre, Pascal Rischmann, Bernard Malavaud, Olivier Cuvillier. Sphingosine kinase-1 is central to androgen-regulated prostate cancer growth and survival. PloS one. 2009 Nov; 4(11):e8048. doi: 10.1371/journal.pone.0008048. [PMID: 19956567]
  • Oliver Sartor, Leonard G Gomella, Paul Gagnier, Karen Melich, Rebekkah Dann. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design. The Canadian journal of urology. 2009 Oct; 16(5):4806-12. doi: NULL. [PMID: 19796455]
  • Rohini Kashimshetty, Varsha G Desai, Vijay M Kale, Taewon Lee, Carrie L Moland, William S Branham, Lee S New, Eric C Y Chan, Husam Younis, Urs A Boelsterli. Underlying mitochondrial dysfunction triggers flutamide-induced oxidative liver injury in a mouse model of idiosyncratic drug toxicity. Toxicology and applied pharmacology. 2009 Jul; 238(2):150-9. doi: 10.1016/j.taap.2009.05.007. [PMID: 19442681]
  • Ajeet Kumar Singh, Akash Chaurasiya, Gaurav K Jain, Anshumali Awasthi, Dinesh Asati, Gautam Mishra, Roop K Khar, Rama Mukherjee. High performance liquid chromatography method for the pharmacokinetic study of bicalutamide SMEDDS and suspension formulations after oral administration to rats. Talanta. 2009 Jun; 78(4-5):1310-4. doi: 10.1016/j.talanta.2009.01.058. [PMID: 19362193]
  • Jeffrey Turner, Uzair Chaudhary. Dramatic prostate-specific antigen response with activated hemicellulose compound in metastatic castration-resistant prostate cancer. Anti-cancer drugs. 2009 Mar; 20(3):215-6. doi: 10.1097/cad.0b013e3283163c26. [PMID: 19104437]